Stryker (SYK): Mako Surgical Robots, Layer 7 of the Robotics Stack
from The Robot Investor
15m 39s
Striker is a $25.1 billion medical device company with a leading robotic system, Mako, used in joint replacement surgeries. The robot is a key driver in Striker’s orthopedic business, with over two-thirds of U.S. knee procedures performed using it. Financially, the company posted strong results in Q2 2026, including 9.4% sales growth and a 27.4% operating margin, backed by $3.5 billion in cash. However, significant risks emerge from supply chain issues in its vascular division—especially after a disputed cyberattack in March 2026—and softness in hip sales due to delayed procedures and European market conditions. Competitors like Johnson & Johnson and Zimmer Biomet are scaling their own robotic systems, adding pressure. Despite these challenges, Striker’s Mako system remains a strong competitive moat. The stock declined sharply in September, now trading near its 52-week low, but valuation appears more attractive than in July, though it’s not clearly a bargain without a robust second-half recovery. The company’s strategy includes future acquisitions and an FDA-approved above-knee vascular product expected by mid-2027. For investors, Striker is best viewed as a medical device company with a robotics edge, not a pure-play robotics stock. Casual investors should assess risk tolerance for vascular, hip, and cyber-related vulnerabilities. Key watchpoints include Q3 results on October 29, focusing on vascular sales, hip growth, and guidance stability, as the company must deliver strong second-half performance to meet full-year targets.
Quick heads up before we start.
This is the robot investor, and we should mention
we're both bots, Theo and I are AI.
- Which is a polite way of saying
nothing you hear today is investment advice.
We can be wrong, same as anyone.
We just say it with more confidence.
- So if something catches your ear,
go check it yourself against a primary source
before you do anything with real money.
- Right, do your own homework.
Okay, let's get into it.
Welcome to the robot investor.
I'm Elena Vance.
- And I'm Theo Brooks, the guy with a normal broker jab
and a lot of questions.
Elena, today is a company I think I've actually heard of
for my own doctor's office, Striker.
- Probably.
Striker is a big medical device company
and it sits in layer seven of our robotic stack.
Medical and surgical robotics.
It makes the make a robot,
which helps surgeons replace knees and hips.
A robot that operates on people.
Okay, that's either very cool
or the plot of a movie I'm not watching.
- Lest dramatic than the movie.
The surgeon is in control,
but here's the hook for today.
In early September,
Striker's chief financial officer spoke
at a health care conference,
said supply problems at one of its businesses
could last longer than hoped
and the shares fell about 9.7%
between Tuesday and Wednesday's open,
according to MedTech Dive.
So a company with a market leading robot
had a rough September.
- Yes, and the question we want to answer
is whether that's a wobble in a great business
or a warning sign.
As always, I'll separate with the sources, say,
from what I'm interpreting.
- Start simple.
What does Striker actually do
and where does the robot fit?
- Striker is a medical technology company,
according to Medical Device Network.
It had about 25.1 billion dollars in revenue in 2025,
up 11.2%.
That revenue comes from many things, orthopedics,
which means joints and bones,
plus endoscopy cameras, surgical instruments,
neuro-technology and a vascular business
that came from buying a company called Inari Medical.
- So the robot is one product line in a giant catalog.
- Right, and that's the honest framing
for a casual investor.
Striker is not a robotic stock.
It's a medical device company
that owns a very important robot.
In 2025, orthopedics was about 9.46 billion dollars
of the 25 billion.
And Striker doesn't break out Mako's own revenue
in anything I found.
So I can't tell you what percentage of sales
is the robot itself.
- Okay, so what does Mako do?
Think of it as a precision assistant for the surgeon.
In the traditional system,
the surgeon plans the operation ahead of time
from a CT scan, and the robotic arm helps guide the cuts
so they stay inside that plan.
Medtech dive describes it that way.
The newest version, Mako 4,
is described as covering knee, hip and spine procedures
with a shoulder feature planned
for late in the first half of this year.
- And Striker has been at this awhile?
- Striker acquired Mako in 2013.
And here's the number that matters.
In the fourth quarter of 2025 call,
as reported by medical device network,
management said the installed base
was over 3,000 systems worldwide.
And that exiting the year,
over two thirds of U.S. knee procedures,
and over one third of U.S. hip procedures at Striker,
were performed on Mako.
- Wait, careful.
Is that two thirds of all U.S. knee replacements
or two thirds of strikers?
- Good catch, Theo.
The wording in the article is ambiguous,
and I can't tell which it means from that source alone.
So please don't hear it as Striker doing
two thirds of the whole market.
Either way, it tells us Mako is now
a big part of how Striker does joint replacement.
- Got it, so where's the money?
The robot or something else?
- This part is my interpretation.
Build on what Striker says.
The robot is a system a hospital buys,
but the surgeon then uses Striker's knee
and hip implants with it.
Striker executive Keith Evans told Medtech Dive
that a new handheld version, Mako RPS,
is meant to help convert more customers
to Striker's triathlon knee system.
An ortho world credits Mako
with much of Striker's roughly 6.5% knee market share gain
over the last decade.
So the robot looks like a way to win the implant business.
- So it's less a product, more a customer magnet.
That's my read of it, not a quote.
- Okay, bull case.
Why would someone own this?
- Four things.
First, adoption is still early.
Zimmer Biomet, a competitor, says 80% of U.S. surgeons
don't use robotics and closer to 90% internationally
per ortho world.
Even with Striker's lead, a lot of surgeons
haven't made the switch.
- So there's runway.
Second, momentum in the machines themselves.
Striker said its second quarter of 2026
was the best ever second quarter
for Mako installations, both in the U.S. and internationally.
Mako has been used in more than two and a half million
procedures globally and is installed in 47 countries.
Capital equipment back orders were also described
as strong by the chief financial officer in September.
- Back orders, meaning hospitals are waiting in line
to buy robots?
Capital equipment back orders, yes,
which is a good sign for demand.
Third, the new handheld Mako RPS
began its full U.S. commercial launch in the second quarter.
It's aimed at surgeons who don't use the traditional system
and Striker sees strong interest
from outpatient surgery centers, per MedTech dive.
That widens the customer base.
- And fourth?
- Financial quality.
Second quarter sales were $6.59 billion,
up 9.4% per mass device.
Adjusted earnings per share were $3.69,
up 17.9%.
Adjusted operating margin was 27.4%,
up 170 basis points.
And the company says it has about three and a half billion
dollars in cash and securities
and plans to resume buybacks.
- Basis points, translate for the people in the car.
100 basis points is one percentage point,
so margin improved about 1.7 percentage points.
Of every dollar of sales,
Striker kept roughly a couple of cents more
as operating profit than a year earlier.
- Now the part I'm nervous about, the bear case.
- Let's give it real weight because it's substantial.
Start with the cyber attack.
On March 11th, 2026, Striker disclosed in a filing
that it had suffered a severe global disruption
to its Microsoft environment,
according to bleeping computer.
A group called Handala,
which that article describes as Iran-linked,
claimed responsibility,
and claimed to have wiped more than 200,000 systems.
Bleeping computer says those claims are unverified,
and Striker's own filing said it had no indication
of ransomware or malware,
and believed the incident was contained.
- So the details are disputed,
but the disruption was real.
- The company itself called it severe,
and the after-effects are the issue.
Second, there's the vascular business.
Striker bought Inari Medical for about $4.9 billion.
In the second quarter,
US peripheral vascular sales fell 6.7% organically
because of an operational disruption,
and the company said a supply problem
at one Inari plant created a significant backorder
and lost sales.
- And then September.
- Then September,
the chief financial officer said the vascular supply problems
from the cyber attack might extend into the fourth quarter
when Striker had hoped to fix them by the third.
He also said hip sales were slower than expected,
citing a softer year for joint replacements in Europe,
seasonality in the US,
and some patients delaying procedures
over financial concerns.
He also named the lack of a hip impactor product
as a competitive disadvantage.
Guidance was not changed.
Did analysts panic?
- Mixed.
Stifle cut its price target from $360 to $330 on September 30th,
but kept a buy rating per market beat
as relayed by ad hoc news.
Back in July,
BTIG cut its target from 371 to 358,
and noted that hitting full-year guidance
needs a significant second half step up.
First half organic growth was about 5.7%,
and the full-year guide is 8.3 to 9.3.
- So the second half has to carry the year.
- That's the math, yes.
Third, competition.
Johnson and Johnson's vellus system
had reached 110,000 procedures across 30 countries
by early 2025, per ortho world,
and Zimmer Biomet has its Rosa system
and is adding another autonomous platform through monogram.
Striker says Mako can already operate autonomously,
but hasn't turned that on, saying there's no demand.
If that changes, competitors might use it
as a selling point.
That last bit is my speculation.
- And one more, right?
The big picture one.
- The robot doesn't protect you from everything else.
Mako had a record quarter and the stocks still fell
because the vascular, hip, and cyber problems
were in other parts of the company.
That's what it means to own a conglomerate
of medical devices in soul of a pure robotic spec.
numbers time where's the stock and is it expensive add Hawke news reported
striker closed at two seventy five forty three on October 2nd with a market
value of about one hundred five point six billion dollars the 52 week range was
two sixty seven to three ninety two fifty five so it's near the bottom of its
year out and the analysts according to market beat as relayed there twenty four
analysts nineteen by five hold the average twelve month target was about three
seventy two sixty four with a range from two ninety eight to four sixty five
those are forecast from the analysts not facts and targets get cut after bad
news as stifle just showed and valuation in english here's my own arithmetic
so label it as mine strikers guided adjusted earnings per share is fourteen
ninety five to fifteen ten divide the october second price by the middle of
that about fifteen dollars and you get roughly eighteen times forward
adjusted earnings back in july simply wall street computed a trailing price to
earnings ratio near forty versus a medical equipment industry average
around twenty eight but that used a different earnings measure and a much higher
price the honest lesson is that the valuation picture depends heavily on which
earnings number you use so check it yourself
so it's cheaper than it was but not obviously a bargain
i'd say it's cheaper than it was in july whether it's cheap depends on whether
the second half recovery shows up
alaina you always ask this what would have to be true for the thesis to work
four things one the vascular supply problems actually get fixed so that business
returns to growth management said it expects that in the third and fourth
quarters and the chief financial officer said inventory may not be where it
should be until the fourth two the second half acceleration is real meaning
organic growth has to climb well above the first half pace three makeo keeps
converting surgeons and pulling implants along with it including through the
handheld version and four competitors like johnson and johnson and zimmer
don't close the gap quickly and what breaks it another slip and vascular hips
that stays soft or consumers delaying surgeries for longer also the oil and
raw material cost pressures management mentioned none of those are robot
problems which circles back to the point may go is a strong competitive asset
inside a business that still has to execute everywhere else so is striker a
robotics stock or robotics option honest answer robotics is a competitive
advantage not the whole stock it's the lever that helps the core joint
replacement business wind share I'd call it a medical device company with a
robotics mode and I'd weigh it that way robotics enthusiasts who want a pure
play will be disappointed and that's fine last big one what should a casual
investor watch from here the date to circle is October 29th striker will
release third quarter results around 405 Eastern with a webcast at 430 things
to listen for vascular sales and whether back orders are manageable as
management promised hip growth make-o installations the early rollout of the
handheld version and whether organic growth is trending toward that 8.3 to 9.3
percent range also whether they keep or change the guidance and on a longer
view management mentioned acquisitions as the top use of cash and they said
they're watching the FDA on an above the knee vascular product that could sell
before the end of the year with another clinical data readout around mid 2027
those aren't robot stories but they affect the stock and the personal finance
angle how much attention does this deserve in a normal portfolio I can't tell
you how to invest and neither of us is an advisor what I can say is that if you
own a broad healthcare or medical device fund you may already own striker check
before adding more of the same thing and if you own it for the robot make sure
you're comfortable owning the vascular hip and cyber risks that come with it my
favorite part of that is check before adding more of the same thing because I've
done that three times with one index I wasn't going to say anything let's rap
give me the one minute version striker is a 25 billion dollar medical
device company that owns the leading joint replacement robot the bowl case is
early adoption record make-o installs a new handheld robot and solid margins the
bear case is a cyber attack that is still causing supply headaches soft hips
rising competition and a guidance that needs a strong second half the stock fell
hard in September and sits near the bottom of its 52 week range as of October
2nd robotics here is a mode not the whole thesis and my version great robot big
company messy year check the October 29th report that's about right as always
this was an AI generated show we're not financial advisors nothing here is
investment advice and you should verify everything against primary sources like
strikers investor relations page and its filings thanks for listening to the
robot investor do your own homework and we'll see you next time goodbye
Podcast Summary
Key Points:
Striker is a medical device company with a leading robotic joint replacement system, Mako, which operates in a key but not dominant portion of its business.
Mako is used in over two-thirds of U.S. knee and one-third of hip replacements, indicating strong adoption and a key driver of Striker’s orthopedic market share growth.
Strong financial performance includes 9.4% sales growth, 17.9% EPS growth, and a 27.4% operating margin in Q2 2026, supported by solid cash reserves and buyback plans.
Despite strong robot adoption, the company faces significant headwinds from vascular supply issues, a cyberattack disrupting operations, and weaker-than-expected hip sales.
The bear case includes prolonged supply problems from Inari Medical, slower surgical adoption, competitive threats from Johnson & Johnson and Zimmer Biomet, and uncertainty in second-half performance.
The stock fell sharply in September, trading near its 52-week low, though analysts maintain a buy rating with modest target cuts reflecting risk concerns.
Striker is not a pure-play robotics stock; the robot is a competitive advantage that enables implant sales, not the core business driver.
Key upcoming events include Q3 results on October 29, where investors should monitor vascular recovery, hip growth, Mako installations, and guidance revisions.
Summary:
1 billion medical device company with a leading robotic system, Mako, used in joint replacement surgeries. S. knee procedures performed using it.
5 billion in cash. However, significant risks emerge from supply chain issues in its vascular division—especially after a disputed cyberattack in March 2026—and softness in hip sales due to delayed procedures and European market conditions. Competitors like Johnson & Johnson and Zimmer Biomet are scaling their own robotic systems, adding pressure.
Despite these challenges, Striker’s Mako system remains a strong competitive moat. The stock declined sharply in September, now trading near its 52-week low, but valuation appears more attractive than in July, though it’s not clearly a bargain without a robust second-half recovery. The company’s strategy includes future acquisitions and an FDA-approved above-knee vascular product expected by mid-2027.
For investors, Striker is best viewed as a medical device company with a robotics edge, not a pure-play robotics stock. Casual investors should assess risk tolerance for vascular, hip, and cyber-related vulnerabilities. Key watchpoints include Q3 results on October 29, focusing on vascular sales, hip growth, and guidance stability, as the company must deliver strong second-half performance to meet full-year targets.
FAQs
Striker is a medical device company with major revenue from orthopedics, endoscopy, and vascular products. Its robot, Mako, is a precision tool used by surgeons to replace knees and hips, acting as a key product in its joint replacement business.
Mako is a major part of Striker's orthopedic success, with over two-thirds of U.S. knee replacements and one-third of hip replacements performed using it. However, Striker does not publicly break out Mako’s specific revenue share.
Strong growth in second-quarter sales, improved operating margins, a growing installed base of over 3,000 Mako systems, and the launch of a new handheld version (Mako RPS) that could expand surgeon adoption.
Supply issues in its vascular business, a cyberattack in 2026 that disrupted operations, slower-than-expected hip sales, and rising competition from rivals like Johnson & Johnson and Zimmer Biomet.
No, Striker is not a pure robotics stock. It’s a medical device company with a robotics technology as a competitive advantage, not its core business.
Investors should monitor vascular sales, hip growth, Mako installations, the performance of the new handheld Mako RPS, and whether organic growth reaches the company’s full-year guidance of 8.3% to 9.3%.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.